BXRX Baudax Bio, Inc. Stock Quote

BXRX [NASD]

Index	-	P/E	-	EPS (ttm)	-5.85	Insider Own	1.10%	Shs Outstand	42.64M	Perf Week	18.94%
Market Cap	68.48M	Forward P/E	-	EPS next Y	-0.76	Insider Trans	0.00%	Shs Float	25.91M	Perf Month	61.03%
Income	-66.40M	PEG	-	EPS next Q	-0.59	Inst Own	16.50%	Short Float	5.38%	Perf Quarter	-0.63%
Sales	0.40M	P/S	171.21	EPS this Y	57.10%	Inst Trans	-0.01%	Short Ratio	0.40	Perf Half Y	-54.49%
Book/sh	-2.46	P/B	-	EPS next Y	81.70%	ROA	-100.10%	Target Price	-	Perf Year	-81.59%
Cash/sh	0.56	P/C	2.78	EPS next 5Y	-	ROE	168.90%	52W Range	0.97 - 10.14	Perf YTD	55.45%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-84.52%	Beta	-
Dividend %	-	Quick Ratio	1.40	Sales past 5Y	-	Gross Margin	-	52W Low	61.86%	ATR	0.13
Employees	24	Current Ratio	1.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	68.61	Volatility	15.63% 9.02%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	154.80%	Profit Margin	-	Rel Volume	3.16	Prev Close	1.70
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	3.52M	Price	1.57
Recom	1.70	SMA20	34.29%	SMA50	39.11%	SMA200	-40.23%	Volume	10,858,940	Change	-7.65%

May-15-20

Initiated

JMP Securities

Mkt Outperform

$13

Jan-21-21 09:29AM	Baudax Bio Announces Exercise of Warrants for Gross Proceeds of $13.4 Million GlobeNewswire -7.65%
Jan-06-21 07:00AM	Baudax Bio to Present at the H.C. Wainwright BioConnect 2021 Conference GlobeNewswire +11.01%
Dec-17-20 07:00AM	Baudax Bio Announces $12 Million Offering Priced at a Premium to Market GlobeNewswire
Dec-08-20 08:40AM	Implied Volatility Surging for Baudax Bio (BXRX) Stock Options Zacks
Dec-07-20 05:17PM	Is BXRX A Good Stock To Buy Now? Insider Monkey
Nov-30-20 04:05PM	Baudax Bio to Participate in the Piper Sandler 32nd Annual Healthcare Conference GlobeNewswire
Nov-23-20 08:00AM	Baudax Bio Announces $12 Million Offering Priced at a Premium to Market GlobeNewswire
Nov-20-20 07:00AM	Baudax Bio Announces Publication of ANJESO® Network Meta-Analysis in the Peer-Reviewed Journal BMC Anesthesiology GlobeNewswire
Nov-19-20 07:00AM	Baudax Bio Announces an additional Orange Book listed patent for ANJESO® GlobeNewswire
Nov-11-20 05:30AM	Results: Baudax Bio, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates Simply Wall St.
Nov-09-20 07:15AM	Baudax Bio Inc to Host Earnings Call ACCESSWIRE -7.56%
07:05AM	Baudax Bio Reports Third Quarter 2020 Financial Results GlobeNewswire
Nov-02-20 07:05AM	Baudax Bio to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020 GlobeNewswire +5.50%
Oct-20-20 07:00AM	Baudax Bio Provides Commercial and Corporate Update GlobeNewswire -40.15%
Oct-02-20 04:05PM	Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +5.51%
Sep-18-20 07:35AM	Baudax Bio to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit GlobeNewswire
Sep-01-20 03:30PM	Oppenheimer: These 3 Penny Stocks Have Triple-Digit Upside Potential TipRanks +8.57%
Aug-25-20 04:05PM	Baudax Bio Awarded Group Purchasing Agreement with Premier Inc. for ANJESO® GlobeNewswire
Aug-20-20 05:57PM	Baudax Bio Appoints Arnold Baskies, M.D. and Andrew Drechsler to Board of Directors GlobeNewswire
Aug-17-20 12:28PM	Baudax Bio, Inc. (NASDAQ:BXRX): Is Breakeven Near? Simply Wall St.
Aug-10-20 07:15AM	Baudax Bio Reports Second Quarter 2020 Financial Results GlobeNewswire -19.77%
Aug-06-20 04:05PM	Baudax Bio to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020 GlobeNewswire
07:00AM	Baudax Bio Secures Permanent J-Code (J1738) for ANJESO® from Centers for Medicare and Medicaid Services GlobeNewswire
Jul-30-20 04:05PM	Baudax Bio Announces Presentation of New Phase IIIb ANJESO® Data at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Meeting GlobeNewswire
Jul-20-20 07:00AM	Baudax Bio Secures Pharmacy Supplier Agreement with Vizient Inc. for ANJESO® GlobeNewswire
Jul-05-20 02:53PM	Hedge Funds Keep Buying Baudax Bio, Inc. (BXRX) Insider Monkey
Jul-03-20 03:25PM	Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-15-20 07:00AM	Baudax Bio Announces Full Commercial Launch of ANJESO and Receipt of Unique C-Code and Pass-Through Payment Status Effective July 1, 2020 GlobeNewswire +10.96%
Jun-01-20 07:00AM	Baudax Bio Secures $50 Million Credit Facility GlobeNewswire
May-18-20 06:12AM	Baudax Bio, Inc. (NASDAQ:BXRX) Insiders Increased Their Holdings Simply Wall St.
May-08-20 07:00AM	Baudax Bio Reports First Quarter 2020 Financial Results GlobeNewswire
May-05-20 07:00AM	Baudax Bio Announces Presentation of New Phase IIIb ANJESO Data at Digestive Disease Week 2020 GlobeNewswire
May-01-20 04:05PM	Baudax Bio Announces Change in Location of its 2020 Annual Meeting of Shareholders to its Corporate Headquarters GlobeNewswire
Apr-29-20 10:02AM	Healthcare Pro Steven Boyd Is Gobbling Up These 3 Stocks TipRanks
Apr-23-20 07:00AM	Baudax Bio Announces Presentation of New Phase IIIb ANJESO Data at the 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting GlobeNewswire
Apr-07-20 08:00AM	Baudax Bio Announces U.S. Availability of ANJESO (meloxicam) Injection for the Management of Moderate to Severe Pain GlobeNewswire
Apr-03-20 06:40PM	Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-26-20 11:35AM	Baudax Bio Announces Closing of $25 Million Public Offering of Securities GlobeNewswire +11.11%
Mar-24-20 09:15AM	Baudax Bio Announces Pricing of Public Offering of Common Stock and Warrants GlobeNewswire -48.05%
Mar-23-20 04:20PM	Baudax Bio Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
Mar-04-20 11:43AM	Baudax Bio Signs Non-Binding Term Sheet for Debt Facility GlobeNewswire +17.08%
Feb-20-20 04:05PM	Baudax Bio Announces FDA Approval of ANJESO for the Management of Moderate to Severe Pain GlobeNewswire
Feb-19-20 06:16PM	3 Strong Buy Healthcare Stocks With Fast-Approaching Catalysts TipRanks -6.44%
Feb-13-20 04:08PM	Baudax Bio Reports 2019 Annual Financial Results GlobeNewswire
Jan-22-20 07:00AM	Baudax Bio Announces PDUFA Date for Intravenous Meloxicam GlobeNewswire +21.16%

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CHURCHILL WINSTON J	Director	Mar 26	Buy	2.28	6,500	14,820	6,500	Mar 30 08:00 PM
CHURCHILL WINSTON J	Director	Mar 26	Buy	2.44	25,000	61,000	52,782	Mar 30 08:00 PM
Weisman Wayne	Director	Mar 26	Buy	2.29	10,000	22,900	40,582	Mar 27 03:53 PM
ALTOMARI ALFRED	Director	Mar 26	Buy	2.34	5,000	11,700	33,382	Mar 27 03:51 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience